Abstract
Vasoactive intestinal peptide (VIP) has been found to act as a potent anti-inflammatory factor through regulating the production of both anti- and pro-inflammatory mediators and promoting Th2-type responses. In this study, we used Chicken collagen II-induced experimental arthritis (CIA) model in Wistar rats to investigate the potential effects of VIP on rheumatoid arthritis. Our results showed that in vivo treatment of CIA-induced rats with VIP had great protective benefit at both clinical and histological levels. Disease suppression was associated with the inhibition of T cells proliferation, shifting of the immune response toward a Th2-type response and expanded CD4(+)CD25(+) Treg in the periphery, which inhibited autoreactive T cell activation/expansion. In conclusion, the study provides evidence that VIP had great protective effect on CIA through its inhibition actions on pathogenic T cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Arthritis, Experimental / chemically induced
-
Arthritis, Experimental / drug therapy*
-
Arthritis, Experimental / immunology
-
Arthritis, Rheumatoid / drug therapy
-
Arthritis, Rheumatoid / immunology
-
Cell Proliferation
-
Down-Regulation
-
Female
-
Forkhead Transcription Factors / genetics
-
Forkhead Transcription Factors / metabolism
-
Gene Expression Regulation
-
Immunosuppressive Agents / immunology
-
Immunosuppressive Agents / therapeutic use*
-
Lymphocyte Activation / drug effects*
-
Lymphocyte Activation / immunology
-
RNA, Messenger / metabolism
-
Rats
-
Rats, Wistar
-
T-Lymphocytes, Regulatory / drug effects*
-
T-Lymphocytes, Regulatory / immunology
-
Th1 Cells / drug effects
-
Th1 Cells / immunology
-
Th2 Cells / drug effects
-
Th2 Cells / immunology
-
Vasoactive Intestinal Peptide / immunology
-
Vasoactive Intestinal Peptide / therapeutic use*
Substances
-
Forkhead Transcription Factors
-
Foxp3 protein, rat
-
Immunosuppressive Agents
-
RNA, Messenger
-
Vasoactive Intestinal Peptide